Bolstering  ||| S:0 E:11 ||| NNP
Components  ||| S:11 E:22 ||| NNP
of  ||| S:22 E:25 ||| IN
the  ||| S:25 E:29 ||| DT
Immune  ||| S:29 E:36 ||| NNP
Response  ||| S:36 E:45 ||| NNP
Compromised  ||| S:45 E:57 ||| NNP
by  ||| S:57 E:60 ||| IN
Prior  ||| S:60 E:66 ||| NNP
Exposure  ||| S:66 E:75 ||| NNP
to  ||| S:75 E:78 ||| TO
Adenovirus ||| S:78 E:88 ||| NNP
:  ||| S:88 E:90 ||| :
Guided  ||| S:90 E:97 ||| NNP
Formulation  ||| S:97 E:109 ||| NNP
Development  ||| S:109 E:121 ||| NNP
for  ||| S:121 E:125 ||| IN
a  ||| S:125 E:127 ||| DT
Nasal  ||| S:127 E:133 ||| NNP
Ebola  ||| S:133 E:139 ||| NNP
Vaccine  ||| S:139 E:147 ||| NNP
The  ||| S:147 E:151 ||| DT
severity  ||| S:151 E:160 ||| NN
and  ||| S:160 E:164 ||| CC
longevity  ||| S:164 E:174 ||| NN
of  ||| S:174 E:177 ||| IN
the  ||| S:177 E:181 ||| DT
current  ||| S:181 E:189 ||| JJ
Ebola  ||| S:189 E:195 ||| JJ
outbreak  ||| S:195 E:204 ||| NN
highlight  ||| S:204 E:214 ||| VB
the  ||| S:214 E:218 ||| DT
need  ||| S:218 E:223 ||| NN
for  ||| S:223 E:227 ||| IN
a  ||| S:227 E:229 ||| DT
fast-acting  ||| S:229 E:241 ||| JJ
yet  ||| S:241 E:245 ||| RB
long-lasting  ||| S:245 E:258 ||| JJ
vaccine  ||| S:258 E:266 ||| NN
for  ||| S:266 E:270 ||| IN
at-risk  ||| S:270 E:278 ||| JJ
populations  ||| S:278 E:290 ||| NNS
( ||| S:290 E:291 ||| -LRB-
medical  ||| S:291 E:299 ||| JJ
personnel  ||| S:299 E:309 ||| NNS
and  ||| S:309 E:313 ||| CC
rural  ||| S:313 E:319 ||| JJ
villagers ||| S:319 E:328 ||| NNS
)  ||| S:328 E:330 ||| -RRB-
where  ||| S:330 E:336 ||| WRB
repeated  ||| S:336 E:345 ||| VBN
prime-boost  ||| S:345 E:357 ||| JJ
regimens  ||| S:357 E:366 ||| NNS
are  ||| S:366 E:370 ||| VBP
not  ||| S:370 E:374 ||| RB
feasible ||| S:374 E:382 ||| JJ
.  ||| S:382 E:384 ||| .
While  ||| S:384 E:390 ||| IN
recombinant  ||| S:390 E:402 ||| JJ
adenovirus  ||| S:402 E:413 ||| NNS
( ||| S:413 E:414 ||| -LRB-
rAd ||| S:414 E:417 ||| NNP
) ||| S:417 E:418 ||| -RRB-
-based  ||| S:418 E:425 ||| JJ
vaccines  ||| S:425 E:434 ||| NNS
have  ||| S:434 E:439 ||| VBP
conferred  ||| S:439 E:449 ||| JJ
full  ||| S:449 E:454 ||| JJ
protection  ||| S:454 E:465 ||| NN
against  ||| S:465 E:473 ||| IN
multiple  ||| S:473 E:482 ||| JJ
strains  ||| S:482 E:490 ||| NNS
of  ||| S:490 E:493 ||| IN
Ebola  ||| S:493 E:499 ||| NNP
after  ||| S:499 E:505 ||| IN
a  ||| S:505 E:507 ||| DT
single  ||| S:507 E:514 ||| JJ
immunization ||| S:514 E:526 ||| NN
,  ||| S:526 E:528 ||| ,
their  ||| S:528 E:534 ||| PRP$
efficacy  ||| S:534 E:543 ||| NN
is  ||| S:543 E:546 ||| VBZ
impaired  ||| S:546 E:555 ||| VBN
by  ||| S:555 E:558 ||| IN
pre-existing  ||| S:558 E:571 ||| JJ
immunity  ||| S:571 E:580 ||| NN
( ||| S:580 E:581 ||| -LRB-
PEI ||| S:581 E:584 ||| NNP
)  ||| S:584 E:586 ||| -RRB-
to  ||| S:586 E:589 ||| TO
adenovirus ||| S:589 E:599 ||| VB
.  ||| S:599 E:601 ||| .
To  ||| S:601 E:604 ||| TO
address  ||| S:604 E:612 ||| VB
this  ||| S:612 E:617 ||| DT
important  ||| S:617 E:627 ||| JJ
issue ||| S:627 E:632 ||| NN
,  ||| S:632 E:634 ||| ,
a  ||| S:634 E:636 ||| DT
panel  ||| S:636 E:642 ||| NN
of  ||| S:642 E:645 ||| IN
formulations  ||| S:645 E:658 ||| NNS
was  ||| S:658 E:662 ||| VBD
evaluated  ||| S:662 E:672 ||| VBN
by  ||| S:672 E:675 ||| IN
an  ||| S:675 E:678 ||| DT
in  ||| S:678 E:681 ||| IN
vitro  ||| S:681 E:687 ||| JJ
assay  ||| S:687 E:693 ||| NN
for  ||| S:693 E:697 ||| IN
their  ||| S:697 E:703 ||| PRP$
ability  ||| S:703 E:711 ||| NN
to  ||| S:711 E:714 ||| TO
protect  ||| S:714 E:722 ||| VB
rAd  ||| S:722 E:726 ||| JJ
from  ||| S:726 E:731 ||| IN
neutralization ||| S:731 E:745 ||| NN
.  ||| S:745 E:747 ||| .
An  ||| S:747 E:750 ||| DT
amphiphilic  ||| S:750 E:762 ||| JJ
polymer  ||| S:762 E:770 ||| NNS
( ||| S:770 E:771 ||| -LRB-
F16 ||| S:771 E:774 ||| NNP
,  ||| S:774 E:776 ||| ,
FW  ||| S:776 E:779 ||| NNP
∼39,000 ||| S:779 E:786 ||| NNP
)  ||| S:786 E:788 ||| -RRB-
significantly  ||| S:788 E:802 ||| RB
improved  ||| S:802 E:811 ||| VBN
transgene  ||| S:811 E:821 ||| JJ
expression  ||| S:821 E:832 ||| NN
in  ||| S:832 E:835 ||| IN
the  ||| S:835 E:839 ||| DT
presence  ||| S:839 E:848 ||| NN
of  ||| S:848 E:851 ||| IN
anti-Ad  ||| S:851 E:859 ||| JJ
neutralizing  ||| S:859 E:872 ||| JJ
antibodies  ||| S:872 E:883 ||| NNS
( ||| S:883 E:884 ||| -LRB-
NAB ||| S:884 E:887 ||| NNP
)  ||| S:887 E:889 ||| -RRB-
at  ||| S:889 E:892 ||| IN
concentrations  ||| S:892 E:907 ||| NNS
of  ||| S:907 E:910 ||| IN
5  ||| S:910 E:912 ||| CD
times  ||| S:912 E:918 ||| NNS
the  ||| S:918 E:922 ||| DT
50 ||| S:922 E:924 ||| CD
%  ||| S:924 E:926 ||| NN
neutralizing  ||| S:926 E:939 ||| NN
dose  ||| S:939 E:944 ||| NN
( ||| S:944 E:945 ||| -LRB-
ND50 ||| S:945 E:949 ||| NNP
) ||| S:949 E:950 ||| -RRB-
.  ||| S:950 E:952 ||| .
In  ||| S:952 E:955 ||| IN
vivo  ||| S:955 E:960 ||| JJ
performance  ||| S:960 E:972 ||| NN
of  ||| S:972 E:975 ||| IN
rAd  ||| S:975 E:979 ||| JJ
in  ||| S:979 E:982 ||| IN
F16  ||| S:982 E:986 ||| NNP
was  ||| S:986 E:990 ||| VBD
compared  ||| S:990 E:999 ||| VBN
with  ||| S:999 E:1004 ||| IN
unformulated  ||| S:1004 E:1017 ||| JJ
virus ||| S:1017 E:1022 ||| NN
,  ||| S:1022 E:1024 ||| ,
virus  ||| S:1024 E:1030 ||| NN
modified  ||| S:1030 E:1039 ||| VBN
with  ||| S:1039 E:1044 ||| IN
poly ||| S:1044 E:1048 ||| NNS
( ||| S:1048 E:1049 ||| -LRB-
ethylene ||| S:1049 E:1057 ||| NN
)  ||| S:1057 E:1059 ||| -RRB-
glycol  ||| S:1059 E:1066 ||| NNS
( ||| S:1066 E:1067 ||| -LRB-
PEG ||| S:1067 E:1070 ||| NNP
) ||| S:1070 E:1071 ||| -RRB-
,  ||| S:1071 E:1073 ||| ,
and  ||| S:1073 E:1077 ||| CC
virus  ||| S:1077 E:1083 ||| NN
incorporated  ||| S:1083 E:1096 ||| VBN
into  ||| S:1096 E:1101 ||| IN
poly ||| S:1101 E:1105 ||| NNS
( ||| S:1105 E:1106 ||| -LRB-
lactic-co-glycolic ||| S:1106 E:1124 ||| NNP
)  ||| S:1124 E:1126 ||| -RRB-
acid  ||| S:1126 E:1131 ||| NN
( ||| S:1131 E:1132 ||| -LRB-
PLGA ||| S:1132 E:1136 ||| NNP
)  ||| S:1136 E:1138 ||| -RRB-
polymeric  ||| S:1138 E:1148 ||| JJ
beads ||| S:1148 E:1153 ||| NN
.  ||| S:1153 E:1155 ||| .
Histochemical  ||| S:1155 E:1169 ||| JJ
analysis  ||| S:1169 E:1178 ||| NN
of  ||| S:1178 E:1181 ||| IN
lung  ||| S:1181 E:1186 ||| NN
tissue  ||| S:1186 E:1193 ||| NN
revealed  ||| S:1193 E:1202 ||| VBD
that  ||| S:1202 E:1207 ||| IN
F16  ||| S:1207 E:1211 ||| NNP
promoted  ||| S:1211 E:1220 ||| VBD
strong  ||| S:1220 E:1227 ||| JJ
levels  ||| S:1227 E:1234 ||| NNS
of  ||| S:1234 E:1237 ||| IN
transgene  ||| S:1237 E:1247 ||| JJ
expression  ||| S:1247 E:1258 ||| NN
in  ||| S:1258 E:1261 ||| IN
naive  ||| S:1261 E:1267 ||| JJ
mice  ||| S:1267 E:1272 ||| NNS
and  ||| S:1272 E:1276 ||| CC
those  ||| S:1276 E:1282 ||| DT
that  ||| S:1282 E:1287 ||| WDT
were  ||| S:1287 E:1292 ||| VBD
exposed  ||| S:1292 E:1300 ||| VBN
to  ||| S:1300 E:1303 ||| TO
adenovirus  ||| S:1303 E:1314 ||| VB
in  ||| S:1314 E:1317 ||| IN
the  ||| S:1317 E:1321 ||| DT
nasal  ||| S:1321 E:1327 ||| JJ
cavity  ||| S:1327 E:1334 ||| NN
28  ||| S:1334 E:1337 ||| CD
days  ||| S:1337 E:1342 ||| NNS
prior  ||| S:1342 E:1348 ||| RB
to  ||| S:1348 E:1351 ||| TO
immunization ||| S:1351 E:1363 ||| VB
.  ||| S:1363 E:1365 ||| .
Multiparameter  ||| S:1365 E:1380 ||| JJ
flow  ||| S:1380 E:1385 ||| NN
cytometry  ||| S:1385 E:1395 ||| VBZ
revealed  ||| S:1395 E:1404 ||| VBN
that  ||| S:1404 E:1409 ||| IN
F16  ||| S:1409 E:1413 ||| CD
induced  ||| S:1413 E:1421 ||| NNS
significantly  ||| S:1421 E:1435 ||| RB
more  ||| S:1435 E:1440 ||| RBR
polyfunctional  ||| S:1440 E:1455 ||| JJ
antigen-specific  ||| S:1455 E:1472 ||| JJ
CD8+  ||| S:1472 E:1477 ||| CD
T  ||| S:1477 E:1479 ||| NN
cells  ||| S:1479 E:1485 ||| NNS
simultaneously  ||| S:1485 E:1500 ||| RB
producing  ||| S:1500 E:1510 ||| VBG
IFN-γ ||| S:1510 E:1515 ||| JJ
,  ||| S:1515 E:1517 ||| ,
IL-2 ||| S:1517 E:1521 ||| NNP
,  ||| S:1521 E:1523 ||| ,
and  ||| S:1523 E:1527 ||| CC
TNF-α  ||| S:1527 E:1533 ||| JJ
than  ||| S:1533 E:1538 ||| IN
other  ||| S:1538 E:1544 ||| JJ
test  ||| S:1544 E:1549 ||| NN
formulations ||| S:1549 E:1561 ||| NNS
.  ||| S:1561 E:1563 ||| .
These  ||| S:1563 E:1569 ||| DT
effects  ||| S:1569 E:1577 ||| NNS
were  ||| S:1577 E:1582 ||| VBD
not  ||| S:1582 E:1586 ||| RB
compromised  ||| S:1586 E:1598 ||| VBN
by  ||| S:1598 E:1601 ||| IN
PEI ||| S:1601 E:1604 ||| NNP
.  ||| S:1604 E:1606 ||| .
Data  ||| S:1606 E:1611 ||| NNS
from  ||| S:1611 E:1616 ||| IN
formulations  ||| S:1616 E:1629 ||| NNS
that  ||| S:1629 E:1634 ||| WDT
provided  ||| S:1634 E:1643 ||| VBD
partial  ||| S:1643 E:1651 ||| JJ
protection  ||| S:1651 E:1662 ||| NN
from  ||| S:1662 E:1667 ||| IN
challenge  ||| S:1667 E:1677 ||| NN
consistently  ||| S:1677 E:1690 ||| RB
identified  ||| S:1690 E:1701 ||| VBN
specific  ||| S:1701 E:1710 ||| JJ
immunological  ||| S:1710 E:1724 ||| JJ
requirements  ||| S:1724 E:1737 ||| NNS
necessary  ||| S:1737 E:1747 ||| JJ
for  ||| S:1747 E:1751 ||| IN
protection ||| S:1751 E:1761 ||| NN
.  ||| S:1761 E:1763 ||| .
This  ||| S:1763 E:1768 ||| DT
approach  ||| S:1768 E:1777 ||| NN
may  ||| S:1777 E:1781 ||| MD
be  ||| S:1781 E:1784 ||| VB
useful  ||| S:1784 E:1791 ||| JJ
for  ||| S:1791 E:1795 ||| IN
development  ||| S:1795 E:1807 ||| NN
of  ||| S:1807 E:1810 ||| IN
formulations  ||| S:1810 E:1823 ||| NNS
for  ||| S:1823 E:1827 ||| IN
other  ||| S:1827 E:1833 ||| JJ
vaccine  ||| S:1833 E:1841 ||| NN
platforms  ||| S:1841 E:1851 ||| NNS
that  ||| S:1851 E:1856 ||| WDT
also  ||| S:1856 E:1861 ||| RB
employ  ||| S:1861 E:1868 ||| VB
ubiquitous  ||| S:1868 E:1879 ||| JJ
pathogens  ||| S:1879 E:1889 ||| NN
as  ||| S:1889 E:1892 ||| IN
carriers  ||| S:1892 E:1901 ||| NNS
like  ||| S:1901 E:1906 ||| IN
the  ||| S:1906 E:1910 ||| DT
influenza  ||| S:1910 E:1920 ||| JJ
virus ||| S:1920 E:1925 ||| NN
.  ||| S:1925 E:1927 ||| .
